Voloridge Investment Management, LLC Viking Therapeutics, Inc. Transaction History

Voloridge Investment Management, LLC

  • $26.2 Billion
  • Q2 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023
SELL
$14.84 - $24.79 $2.15 Million - $3.6 Million
-145,043 Reduced 36.74%
249,724 $4.05 Million
Q1 2023

May 15, 2023
BUY
$8.08 - $17.33 $3.19 Million - $6.84 Million
394,767 New
394,767 $6.57 Million
Q1 2019

May 15, 2019
SELL
$7.58 - $9.94 $159,111 - $208,650
-20,991 Closed
0 $0
Q4 2018

Feb 14, 2019
BUY
$7.16 - $16.21 $61,239 - $138,644
8,553 Added 68.77%
20,991 $161,000
Q3 2018

Nov 14, 2018
BUY
$9.7 - $19.65 $120,648 - $244,406
12,438 New
12,438 $217,000

Others Institutions Holding VKTX

# of Institutions
442
Shares Held
63.3M
Call Options Held
6.23M
Put Options Held
2.97M
View Full List

About Viking Therapeutics, Inc.

VKTX Quotes by TradingView
  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $4.83B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Voloridge Investment Management, LLC Portfolio

Follow Voloridge Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voloridge Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voloridge Investment Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email